• IN10028 (second-generation FAKi): Designed to advance beyond first-generation FAKi, with encouraging preclinical potency, target engagement and antitumor activity; an important new clinical-stage asset and potential combination backbone.
  • Novel payload and ADC innovation (IND-ready by Q3 2027): InxMed is developing differentiated ADCs featuring novel payload approaches, including MAPK-directed TM2 technology, with goal to target two key resistance MOAs of RASi, YAP and MAPK alterations.  These two MOAs are essential for treatment resistance.
  • RAS / FAK / MAPK combinations: Promising internal preclinical xenograft findings include tumor regression in a KRAS mutated colorectal cancer and PDX models when FAKi like IN10028 (Figure 2) and a TM2-payload ADC were added to RAS-directed therapy. 

这里是标题一h1占位文字